p3

Cambridge Healthtech Institute’s 7th Annual

Antibody-Drug Conjugates

Next-Gen Engineering

January 21-22, 2020

Part of the Antibody Therapeutics pipeline

 

Antibody-Drug Conjugates have demonstrated their ability to deliver cytotoxic small-molecule drugs through a selective and targeted mechanism in the fight against cancer. In recent years, ADCs have entered almost 600 clinical trials with more than 60 distinct ADC molecules currently under development. Despite the enormous promise, a low therapeutic index has plagued ADC development, particularly for treating solid tumors.

Cambridge Healthtech Institute’s Antibody-Drug Conjugates conference explores the engineering finesse required to achieve the crucial balance between efficacy and safety, thus leading the way to more potent and targeted molecules. Case studies and data will be shared that illustrate the ongoing efforts to engineer ADCs, move them into the clinic, and conquer cancer.

 

Coverage will include, but is not limited to:

  • Balancing safety and efficacy
  • How to make ADCs work in solid tumors
  • Potency of the payload-warhead
  • ADME-PK in ADC safety and efficacy
  • Developing new targets
  • ADC potency
  • Improving Therapeutic Index (TI)
  • Site-specific conjugation
  • New approaches to conjugation
  • Linker technology
  • Next-generation linker payloads
  • Targeting delivery
  • Warhead design
  • Cytotoxic warheads
  • Drug-antibody ratio
  • Emerging research
  • Half-life
  • PK/PD
  • Aggregation
  • Stability
  • Matching up warhead, linker, and target
  • Limiting off-target side effects
  • Translating ADCs from pre-clinical development into the clinic
  • Mechanism of Action (MOA)
  • Selecting first human dose

 

* The program is subject to change without notice, due to unforeseen reason.







2020 Conferences & Training Seminars